CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 进入新“相”：利用相分离改善 CAR-T 功能
英文原题：CAR-T Entering a New "Phase": Improving CAR-T Function by Harnessing Phase Separation.
查看英文原题
CAR-T Entering a New "Phase": Improving CAR-T Function by Harnessing Phase Separation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
生物分子凝聚已成为组织生物过程（包括免疫应答）的一种普遍原则。Xu 及其同事最近报道，T 细胞受体复合物 CD3 亚基的胞质尾区与嵌合抗原受体（CAR）融合后，可通过液-液相分离促进 CAR 凝聚。通过序列工程，作者鉴定出可增强免疫突触成熟和共受体信号传导的修饰 CD3 序列，从而提高体外细胞毒性，并增强小鼠异种移植模型中的抗肿瘤效果。这些结果表明，生物分子凝聚可被用来改善 CAR-T 细胞的功能，凸显了开发下一代细胞疗法的一种令人兴奋的策略。
展开英文摘要原文
Biomolecular condensation has emerged as a general principle in organizing biological processes, including immune response. Xu and colleagues recently reported that the cytoplasmic tail of the CD3 subunit of the T-cell receptor complex, when fused to a chimeric antigen receptor (CAR), can promote CAR condensation by liquid-liquid phase separation.
Through sequence engineering, the authors identified modified CD3 sequences that enhance the maturation of the immunologic synapse and coreceptor signaling, leading to an improvement in cytotoxicity in vitro and antitumor effects in mouse xenograft models. These results demonstrated that biomolecular condensation could be exploited to improve the function of CAR-T cells, highlighting an exciting strategy for developing next-generation cell therapies.
论文信息
- 作者
- Su X
- 单位
- Department of Cell Biology, Yale School of Medicine, New Haven, Connecticut.
- 期刊
- Cancer research2025 Mar 14
- 原文标识
- PubMed 39879116 · DOI 10.1158/0008-5472.CAN-25-0357
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →